ProteoTech Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

Cavendish Global Health Impact Forum 2014

KIRKLAND, Wash.--()--ProteoTech, Inc., a therapeutic drug discovery development company targeting misfolded proteins and amyloid diseases, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7, New York, NY. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. Michael Moffat, Cavendish co-founder and President, explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of ProteoTech, Inc. research and scientific insights in Alzheimer’s disease, Parkinson’s disease, type 2 diabetes and systemic amyloid disease (including AL, TTR and AA amyloidosis) positions them to make a major contribution to the drug development.”

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to drug development of treatments for many unmet medical needs afflicting populations around the world today,” said Alan Snow, PhD, President and CSO. “We welcome the chance to interact with many of world’s leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. Cavendish Global together with the Global Partnerships Forum and the New York Academy of Sciences organizes the Forum annually in New York.

About ProteoTech

(http://www.proteotech.com)

ProteoTech is a private, therapeutic development Company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolded protein disorders and amyloid diseases. ProteoTech’s lead small molecule compound, SystebrylTM (PTI-110) will soon be entering Phase 1/2 proof-of-concept studies in AL (immunoglobulin light chain) amyloidosis (an orphan disease). Other drugs in the pipeline, include a small molecule drug inhibitor for TTR (transthyretin) amyloidosis, a small molecule drug inhibitor of alpha-synuclein accumulation (for Parkinson’s disease and other synucleinopathies), and a small molecule drug that works both on the beta-amyloid protein and tau protein of Alzheimer’s disease.

For more information: http://www.proteotech.com

About Cavendish Global

(http://cavendishglobal.com)

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States (taking place in New York at the United Nations Headquarters May 5th to 7th 2014), Europe (UK, November 2014, in association with SV Life Sciences, hosted by Oxford University) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015).

For more information: http://cavendishglobal.com

Contacts

ProteoTech, Inc.
Dr. Roger Flugel, 425-823-0400
Chief Business Officer
flugel@proteotech.com
or
Dr. Alan Snow, 425-823-0400
President & Chief Scientific Officer
snow@proteotech.com

Sharing

Contacts

ProteoTech, Inc.
Dr. Roger Flugel, 425-823-0400
Chief Business Officer
flugel@proteotech.com
or
Dr. Alan Snow, 425-823-0400
President & Chief Scientific Officer
snow@proteotech.com